Our in vivo treatment experiments show that targeting HVEM/BTLA pathway with anti-BTLA significantly decreased tumor growth and prolonged OS in FXRhiPD-L1lo LLC tumor–bearing mice, in comparison with those bearing mock LLC tumors. This evidence concerns the gene TNFRSF14 and neoplasm.